Last Updated on October 2, 2024 by The Health Master
New Delhi: Takeda Pharmaceuticals has got the go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) for marketing the gastrointestinal drug, Vedolizumab with additional strength thru the subcutaneous route.
This came in line with the proposal presented by Takeda Pharmaceuticals for the import and marketing of additional strength and a new route of administration of Vedolizumab.
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation.
It is used in the treatment of moderate to severe active ulcerative colitis and Crohn’s disease for patients who have had an inadequate response to, lost response to, or are intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) or other conventional therapies. By blocking its primary target, α4β7 integrin, vedolizumab reduces inflammation in the gut.
Kynteles is used for the treatment of adult patients with moderate to severely active Ulcerative Colitis (UC) and Crohn’s Disease (CD). Vedolizumab is a gut-selective biologic and is approved as an intravenous formulation.
At the recent SEC meeting for Gastroenterology & Hepatology held on 17.12.2021, the committee extensively evaluated the drug maker Takeda Pharmaceuticals‘ proposal for the import and marketing of additional strength and a new route of administration of Vedolizumab.
The committee noted that Vedolizumab through the IV route is already approved for marketing in the country. Furthermore, the proposed additional strength through the subcutaneous route has been approved in the EU, Switzerland, etc.
After detailed deliberation, the committee recommended the grant of marketing permission for Vedolizumab of additional strength thru the subcutaneous route.
Further, the committee directed that the indication should reflect that the additional strength is for the subcutaneous route and only for maintenance purposes.
CDSCO approves Corbevax, Covovax and Molnupiravir for restricted use
DCGI gives nod to Serum India for developing jab against Omicron
DCGI gives approval to Biological E for Corbevax
DCGI gives nod to Sun Pharma arm for Molnupiravir in India
Covaxin gets emergency use approval from DCGI for children above 12 years
DCGI seeks more data from Serum Institute for Covovax Vaccine
These 13 Pharma Companies to launch Anti-COVID Drug Molnupiravir
DCGI gives nod to Serum India for developing jab against Omicron
Common ET Plant to help pharma firms to treat or reuse…
Pharma Firm booked for Rs 1,627 Crore Loan Fraud
Drug industry cheers FSSAI’s removal of ban on Methylcobalamin
USFDA gives tentative nod to Zydus Cadila for Pimavanserin capsules
Molnupiravir: A wonder drug or a limited star?
NPPA fixes retail price of 2 formulations: December 2021
NPPA fixes retail price of 28 formulations: December 2021
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
